ロード中...
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR-ABL inhibitor, nilotinib (AMN107), is significantly more potent against BCR-ABL than imatinib, and is active against many imat...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2007
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1801049/ https://ncbi.nlm.nih.gov/pubmed/17068153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-026377 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|